Literature DB >> 10467385

Measuring handicap in multiple sclerosis.

A J Thompson1.   

Abstract

Handicap, shortly to be renamed participation, is a well defined though somewhat neglected entity which addresses an important aspect of the impact disease has on the individual. It is particularly relevant in Multiple Sclerosis (MS) which has such a major impact on issues such as employment, relationships, transport and social integration. Few validated measuring tools exist, and the generic London Handicap Scale is probably the best currently available but is only appropriate for group comparison. Handicap should be monitored in MS and is particularly appropriate in the evaluation of rehabilitation strategies.

Entities:  

Mesh:

Year:  1999        PMID: 10467385     DOI: 10.1177/135245859900500411

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II).

Authors:  Francesco Patti; Maria Pia Amato; Maria Trojano; Stefano Bastianello; Maria Rosalia Tola; Orietta Picconi; Sabina Cilia; Salvatore Cottone; Luigi M E Grimaldi
Journal:  Qual Life Res       Date:  2011-09-28       Impact factor: 4.147

2.  Validation of the Comprehensive International Classification of Functioning, Disability, and Health Core Set for multiple sclerosis from the perspective of physicians.

Authors:  Stephanie Berno; Michaela Coenen; Andreas Leib; Alarcos Cieza; Jürg Kesselring
Journal:  J Neurol       Date:  2012-01-24       Impact factor: 4.849

3.  The development of ICF Core Sets for multiple sclerosis: results of the International Consensus Conference.

Authors:  Michaela Coenen; Alarcos Cieza; Jenny Freeman; Fary Khan; Deborah Miller; Andrea Weise; Jürg Kesselring
Journal:  J Neurol       Date:  2011-03-04       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.